VYNE CFO Reports 3,420‑Share Withholding for RSU Taxes
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
VYNE Therapeutics Inc. Chief Financial Officer Zeronda Tyler reported a Form 4 disclosing a non‑derivative disposition on 09/30/2025. The filing shows 3,420 shares of common stock were disposed of at a price of $0.335 per share. The filing explains these shares were withheld by the issuer to satisfy tax withholding obligations related to the vesting of restricted stock units. After the reported transaction, the reporting person beneficially owns 111,653 shares, held in a direct ownership form. The Form 4 is signed by an attorney‑in‑fact and contains no other transactions or derivative instruments.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Zeronda Tyler
Role
CHIEF FINANCIAL OFFICER
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 3,420 | $0.335 | $1K |
Holdings After Transaction:
Common Stock — 111,653 shares (Direct)
Footnotes (1)
- [object Object]
FAQ
What did the VYNE (VYNE) Form 4 filed by Zeronda Tyler report?
The Form 4 reports a 9/30/2025 disposition of 3,420 common shares at $0.335 per share, withheld to satisfy tax obligations from RSU vesting.
Who is the reporting person on the Form 4 for VYNE?
The reporting person is Zeronda Tyler, identified as the company's Chief Financial Officer.
Were any derivative securities reported in this Form 4 for VYNE?
No derivative securities (options, warrants, convertible instruments) are reported in the Form 4; only a non‑derivative common stock disposition is shown.